Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.40 |
| ▸ | FBP1 | P09467 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4877595 | 0.81 | KDM4E (0.49) | KDM4EPOLBPDE4DHCAR2MAPT | |
| SCHEMBL3956111 | 0.75 | HCAR2 (0.68) | KDM4EPOLBPDE4DHCAR2MAPT | |
| SCHEMBL5569375 | 0.74 | HCAR2 (0.43) | KDM4EPOLBPDE4DHCAR2MAPT | |
| SCHEMBL23112395 | 0.73 | KDM4E (0.48) | KDM4EPOLBPDE4DMAPTKMT2A | |
| SCHEMBL5763853 | 0.72 | KDM4E (0.47) | KDM4EPOLBPDE4DMAPTKMT2A | |
| SCHEMBL7814443 | 0.70 | PDE4D (0.58) | KDM4EPOLBPDE4DHCAR2MAPT | |
| SCHEMBL9025999 | 0.70 | PDE4D (0.53) | KDM4EPOLBPDE4DMAPTKMT2A | |
| SCHEMBL7309807 | 0.70 | ALDH1A1 (0.44) | KDM4EPOLBMAPTKMT2ALMNA | |
| SCHEMBL26103963 | 0.70 | MAPT (0.47) | KDM4EPOLBMAPTKMT2AMEN1 | |
| SCHEMBL12225758 | 0.69 | HCAR2 (0.51) | KDM4EPOLBHCAR2MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090836-A1 | Pyrazole Compounds Useful In The Treatment Of Inflammation | BIOLIPOX AB (SE) | 2008-04-17 | — | — | US | disclosed |
| EP-1794130-A1 | PYRAZOLE COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006032852-A1 | PYRAZOLE COMPOUNDS USEFUL UIN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090836-A1 | Pyrazole Compounds Useful In The Treatment Of Inflammation | ALOX15, ALOX15B, ALOX12 | KDM4E 3158/4885POLB 2242/4885PDE4D 2303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.